Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Ocean Biomedical, Inc. (OCEA)

Compare
0.0549
+0.0009
+(1.67%)
At close: 4:00:01 PM EDT
0.0500
-0.00
(-8.93%)
After hours: 4:47:31 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for OCEA

Recent News: OCEA

View More
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China
GlobeNewswire 4 days ago
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
GlobeNewswire last month
Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway
GlobeNewswire 2 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
GlobeNewswire 4 months ago
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter
GlobeNewswire 5 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
GlobeNewswire 5 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
GlobeNewswire 7 months ago
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
GlobeNewswire 9 months ago
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease
GlobeNewswire 10 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
GlobeNewswire 11 months ago
View More

Related Tickers

OSRH OSR Holdings, Inc.
1.7200
-8.51%
 
PRTG Portage Biotech Inc.
8.26
-10.70%
 
DRMA Dermata Therapeutics, Inc.
0.9997
-7.44%
 
LPTX Leap Therapeutics, Inc.
0.2913
-4.52%
 
THTX Theratechnologies Inc.
1.4000
0.00%
 
LXRX Lexicon Pharmaceuticals, Inc.
0.4641
+0.72%
 
RNAZ TransCode Therapeutics, Inc.
0.5409
+9.27%
 
SNSE Sensei Biotherapeutics, Inc.
0.3450
-12.44%
 
PSTV Plus Therapeutics, Inc.
1.0200
+7.36%
 
DBVT DBV Technologies S.A.
6.46
-5.28%